What efficacy measures are clinically relevant and should be used in Cochrane Reviews of acute migraine trials?: A viewpoint

Peer Tfelt-Hansen

doi:10.1177/0333102414545347

What efficacy measures are clinically relevant and should be used in Cochrane Reviews of acute migraine trials? A viewpoint

Peer Tfelt-Hansen

Afdeling for Hjerne- og Nervesygdomme

3 Citationer (Scopus)

Abstract

BACKGROUND: Cochrane Reviews are methodologically of high quality but the clinical relevance of analysed efficacy measures (EMs) should also be assessed.

METHODS: The clinical relevance of EMs used in one systematic Cochrane review of oral zolmitriptan for migraine headache was evaluated.

RESULTS: The following EMs were used: pain free at two hours (30%), headache relief at two hours (60%), sustained pain free for 24 hours (19%) and sustained headache relief for 24 hours (39%). These EMs were also used in four other Cochrane reviews of acute migraine treatment. Of these EMs sustained headache relief for 24 h is not judged clinically relevant.

CONCLUSION: Pain free and sustained pain free are clinically relevant, but the responses are rather low, demonstrating that there is a need for improvement of acute drug treatment in migraine.

Originalsprog	Engelsk
Tidsskrift	Cephalalgia : an international journal of headache
Vol/bind	35
Udgave nummer	5
Sider (fra-til)	457-459
ISSN	0333-1024
DOI	https://doi.org/10.1177/0333102414545347
Status	Udgivet - 2015

Adgang til dokumentet

10.1177/0333102414545347

Citationsformater

@article{f146b0e8d0564938a397518a7162ccca,

title = "What efficacy measures are clinically relevant and should be used in Cochrane Reviews of acute migraine trials?: A viewpoint",

abstract = "BACKGROUND: Cochrane Reviews are methodologically of high quality but the clinical relevance of analysed efficacy measures (EMs) should also be assessed.METHODS: The clinical relevance of EMs used in one systematic Cochrane review of oral zolmitriptan for migraine headache was evaluated.RESULTS: The following EMs were used: pain free at two hours (30%), headache relief at two hours (60%), sustained pain free for 24 hours (19%) and sustained headache relief for 24 hours (39%). These EMs were also used in four other Cochrane reviews of acute migraine treatment. Of these EMs sustained headache relief for 24 h is not judged clinically relevant.CONCLUSION: Pain free and sustained pain free are clinically relevant, but the responses are rather low, demonstrating that there is a need for improvement of acute drug treatment in migraine.",

author = "Peer Tfelt-Hansen",

note = "{\textcopyright} International Headache Society 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.",

year = "2015",

doi = "10.1177/0333102414545347",

language = "English",

volume = "35",

pages = "457--459",

journal = "Cephalalgia : an international journal of headache",

issn = "0333-1024",

publisher = "SAGE Publications Ltd",

number = "5",

}

TY - JOUR

T1 - What efficacy measures are clinically relevant and should be used in Cochrane Reviews of acute migraine trials?

T2 - A viewpoint

AU - Tfelt-Hansen, Peer

PY - 2015

Y1 - 2015

N2 - BACKGROUND: Cochrane Reviews are methodologically of high quality but the clinical relevance of analysed efficacy measures (EMs) should also be assessed.METHODS: The clinical relevance of EMs used in one systematic Cochrane review of oral zolmitriptan for migraine headache was evaluated.RESULTS: The following EMs were used: pain free at two hours (30%), headache relief at two hours (60%), sustained pain free for 24 hours (19%) and sustained headache relief for 24 hours (39%). These EMs were also used in four other Cochrane reviews of acute migraine treatment. Of these EMs sustained headache relief for 24 h is not judged clinically relevant.CONCLUSION: Pain free and sustained pain free are clinically relevant, but the responses are rather low, demonstrating that there is a need for improvement of acute drug treatment in migraine.

AB - BACKGROUND: Cochrane Reviews are methodologically of high quality but the clinical relevance of analysed efficacy measures (EMs) should also be assessed.METHODS: The clinical relevance of EMs used in one systematic Cochrane review of oral zolmitriptan for migraine headache was evaluated.RESULTS: The following EMs were used: pain free at two hours (30%), headache relief at two hours (60%), sustained pain free for 24 hours (19%) and sustained headache relief for 24 hours (39%). These EMs were also used in four other Cochrane reviews of acute migraine treatment. Of these EMs sustained headache relief for 24 h is not judged clinically relevant.CONCLUSION: Pain free and sustained pain free are clinically relevant, but the responses are rather low, demonstrating that there is a need for improvement of acute drug treatment in migraine.

U2 - 10.1177/0333102414545347

DO - 10.1177/0333102414545347

M3 - Journal article

C2 - 25135653

SN - 0333-1024

VL - 35

SP - 457

EP - 459

JO - Cephalalgia : an international journal of headache

JF - Cephalalgia : an international journal of headache

IS - 5

ER -

What efficacy measures are clinically relevant and should be used in Cochrane Reviews of acute migraine trials? A viewpoint

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater